Երկիր: Կանադա
Լեզու: անգլերեն
Աղբյուրը: Health Canada
GEMFIBROZIL
NU-PHARM INC
C10AB04
GEMFIBROZIL
600MG
TABLET
GEMFIBROZIL 600MG
ORAL
100
Prescription
FRIBIC ACID DERIVATIVES
Active ingredient group (AIG) number: 0116135002; AHFS:
CANCELLED POST MARKET
2012-09-04
PRODUCT MONOGRAPH NU-GEMFIBROZIL GEMFIBROZIL CAPSULES USP 300 MG GEMFIBROZIL TABLETS USP 600 MG ANTIHYPERLIPIDEMIC AGENT NU A PHARM INC. DATE OF PREPARATION: 50 MURAL STREET, UNITS 1 & 2 November 25, 1993 RICHMOND HILL, ONTARIO DATE OF REVISION: L4B 1E4 February 6, 2004 CONTROL# 089327 1 PRODUCT MONOGRAPH NU-GEMFIBROZIL Gemfibrozil Capsules USP 300 mg Gemfibrozil Tablets USP 600 mg THERAPEUTIC CLASSIFICATION Antihyperlipidemic Agent ACTIONS AND CLINICAL PHARMACOLOGY Gemfibrozil is a lipid regulating agent which decreases serum triglycerides and total cholesterol, and increases high density lipoprotein cholesterol. The lipid-lowering changes occur primarily in the very low density lipoprotein (VLDL) fraction (S f 0-20) rich in triglycerides and to a lesser extent in the low density lipoprotein (LDL) fraction (S f 20-400) rich in cholesterol. Gemfibrozil treatment of patients with elevated triglycerides due to Type IV hyperlipoproteinemia may cause a rise in LDL-cholesterol. In addition, gemfibrozil increases the high density lipoprotein (HDL) cholesterol subfractions, HDL 2 and HDL 3 , as well as apolipoproteins Al and All. Epidemiological studies have shown that both low HDL-cholesterol and high LDL-cholesterol are independent risk factors for coronary heart disease. Depending on the type of hyperlipidemia, pharmacological intervention with gemfibrozil raises HDL-cholesterol and may lower LDL- cholesterol, and may be associated with reduced morbidity due to coronary heart disease as reported in the Helsinki Heart Study, a 5-year primary prevention Phase IV clinical trial. The mechanism of action has not been definitely established. In man, gemfibrozil has been shown to inhibit peripheral lipolysis and to decrease the hepatic extraction of free fatty acids, thus reducing hepatic triglyceride production. Gemfibrozil also inhibits the synthesis and increases clearance of VLDL carrier apolipoprotein B, leading to a decrease in VLDL. 2 Animal studies suggest that gemfibrozil may, in addition to elevating HDL cholester Կարդացեք ամբողջական փաստաթուղթը